ClinicalTrials.gg
Not yet recruitingNCT07584772HERO_2025Updated May 13, 2026

Use of D-Chiro-inositol in Male Functional Hypogonadism Associated With Sexual Dysfunction

An interventional study of D-chiro-inositol in Functional Hypogonadism, sponsored by Cardarelli Hospital. Not yet recruiting. Open to male participants aged 50 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-13.

Sponsored by Cardarelli Hospital · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
35
Allocation
Not applicable
Ages
50 Years to 75 Years
Sex
Male
01

Study summary

A prospective, uncontrolled, non-pharmacological interventional study conducted on men with functional or borderline hypogonadism, aimed at evaluating, after 3 months of supplementation with D-Chiro-inositol, changes in hormonal profile and sexual function.

Read the detailed description

The study involves the recruitment of 35 functional hypogonadal patients aged between 50 and 75 years to the Andrology Unit of the "Antonio Cardarelli" Hospital. At T0 patients will undergo hematochemical evaluation of the following parameters: total and free testosterone, PSA and hematocrit.

At the same time, they will be provided with a self-assessment questionnaire on physical and sexual functioning. The same evaluations will be performed after 3 months of supplementation (T1).

The main endpoint is the intra-subject variation in total and free testosterone levels between T0 and T1.

02

Conditions studied

  • Functional Hypogonadism

Browse trials for

03

In context

Hypogonadism

320 studies on the registry are indexed under Hypogonadism; 39 are open to participants now.

This study's planned enrollment of 35 is below the median of 50 across 243 interventional studies indexed under Hypogonadism.

Browse Hypogonadism studies →

Lead sponsor

Cardarelli Hospital is the lead sponsor of 9 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 75 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men aged between 50 and 75
  • Affected by functional hypogonadism associated with male aging

Exclusion criteria

Exclusion Criteria:

  • Elevated ferritin, PRL, and/or elevated CRP values; diagnosis of primary hypogonadism; diagnosis of organic hypogonadotropic hypogonadism or secondary to other ongoing acute or chronic pathologies; presence of other pituitary deficits.
  • Alcohol use and/or drug abuse, recent hormone treatment, smoking, systemic or endocrine diseases, infection of the male accessory glands, medical history of cryptorchidism or varicocele, and micro-orchidism.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
35 participants (estimated)

Study arms

  • Experimental
    Treated

    Treatment with D-chiro-inositol

    Dietary Supplement: D-chiro-inositol

Interventions

06

What researchers measure

Primary outcomes

  1. Testosterone levels

    Variation of serum testosterone levels

    Time frame: From enrollment to three months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jul 2026; primary completion for Nov 2026, 4 months later.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2026
First posted
May 13, 2026
StartEst.
Jul 1, 2026
Primary completionEst.
Nov 30, 2026
CompletionEst.
Jan 1, 2027
Last update
May 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07584772
Lead sponsor
Cardarelli Hospital
Responsible party
Maurizio Carrino (Dr, Cardarelli Hospital) — Principal investigator
First posted
May 13, 2026
Start date
Jul 1, 2026 (estimated)
Primary completion
Nov 30, 2026 (estimated)
Completion
Jan 1, 2027 (estimated)
Last update
May 13, 2026

Study contacts

Maurizio Carrino, MD
Contact
maurizio.carrino@aocardarelli.it
+39 081 7472474

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Chiro-inositol, (+)-

Start the discussion